166 related articles for article (PubMed ID: 19734170)
1. Tissue penetration of moxifloxacin into human gallbladder wall in patients with biliary tract infections.
Ober MC; Hoppe-Tichy T; Köninger J; Schunter O; Sonntag HG; Weigand MA; Encke J; Gutt C; Swoboda S
J Antimicrob Chemother; 2009 Nov; 64(5):1091-5. PubMed ID: 19734170
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and peritoneal penetration of moxifloxacin in peritonitis.
Stass H; Rink AD; Delesen H; Kubitza D; Vestweber KH
J Antimicrob Chemother; 2006 Sep; 58(3):693-6. PubMed ID: 16895940
[TBL] [Abstract][Full Text] [Related]
3. Moxifloxacin penetration into human gastrointestinal tissues.
Wirtz M; Kleeff J; Swoboda S; Halaceli I; Geiss HK; Hoppe-Tichy T; Büchler MW; Friess H
J Antimicrob Chemother; 2004 May; 53(5):875-7. PubMed ID: 15056642
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of moxifloxacin in patients undergoing continuous venovenous haemodiafiltration.
Fuhrmann V; Schenk P; Jaeger W; Ahmed S; Thalhammer F
J Antimicrob Chemother; 2004 Oct; 54(4):780-4. PubMed ID: 15347636
[TBL] [Abstract][Full Text] [Related]
5. Single- and multiple-dose pharmacokinetics of intravenous moxifloxacin in patients with severe hepatic impairment.
Barth J; Jäger D; Mundkowski R; Drewelow B; Welte T; Burkhardt O
J Antimicrob Chemother; 2008 Sep; 62(3):575-8. PubMed ID: 18515790
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of intravenously administered moxifloxacin in eye compartments: an experimental study.
Tzepi I; Vergados I; Kanellakopoulou K; Papathanassiou M; Kranidioti H; Tsaganos T; Liarakos V; Giamarellos-Bourboulis EJ; Theodossiadis P
Int J Antimicrob Agents; 2009 Feb; 33(2):160-2. PubMed ID: 18947985
[TBL] [Abstract][Full Text] [Related]
7. Penetration of moxifloxacin into the human pancreas following a single intravenous or oral dose.
Wacke R; Förster S; Adam U; Mundkowski RG; Klar E; Hopt UT; Drewelow B
J Antimicrob Chemother; 2006 Nov; 58(5):994-9. PubMed ID: 16956903
[TBL] [Abstract][Full Text] [Related]
8. Concentration of moxifloxacin in plasma and tonsillar tissue after multiple administration in adult patients.
Esposito S; Noviello S; D'Errico G; Motta G; Passali D; Aimoni C; Pilucchi S; Fallani S; Cassetta MI; Mazzei T; Novelli A
J Antimicrob Chemother; 2006 Apr; 57(4):789-92. PubMed ID: 16504997
[TBL] [Abstract][Full Text] [Related]
9. Concentrations of moxifloxacin in plasma and urine, and penetration into prostatic fluid and ejaculate, following single oral administration of 400 mg to healthy volunteers.
Wagenlehner FM; Kees F; Weidner W; Wagenlehner C; Naber KG
Int J Antimicrob Agents; 2008 Jan; 31(1):21-6. PubMed ID: 18054465
[TBL] [Abstract][Full Text] [Related]
10. Penetration of moxifloxacin into bone in patients undergoing total knee arthroplasty.
Malincarne L; Ghebregzabher M; Moretti MV; Egidi AM; Canovari B; Tavolieri G; Francisci D; Cerulli G; Baldelli F
J Antimicrob Chemother; 2006 May; 57(5):950-4. PubMed ID: 16551691
[TBL] [Abstract][Full Text] [Related]
11. Serum concentrations and pharmacokinetics of moxifloxacin in patients undergoing coronary artery bypass graft surgery with cardiopulmonary bypass.
Wiesner G; Martin K; Gertler R; Braun SL; Tassani P; Lange R; Gruber M
Int J Antimicrob Agents; 2013 May; 41(5):473-6. PubMed ID: 23481660
[TBL] [Abstract][Full Text] [Related]
12. Penetration of moxifloxacin into sternal bone of patients undergoing routine cardiopulmonary bypass surgery.
Metallidis S; Charokopos N; Nikolaidis J; Alexiadou E; Lazaraki G; Koumentaki E; Tsona A; Theodoridis G; Nikolaidis P
Int J Antimicrob Agents; 2006 Nov; 28(5):428-32. PubMed ID: 17034992
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of moxifloxacin in non-inflamed cerebrospinal fluid of humans: implication for a bactericidal effect.
Kanellakopoulou K; Pagoulatou A; Stroumpoulis K; Vafiadou M; Kranidioti H; Giamarellou H; Giamarellos-Bourboulis EJ
J Antimicrob Chemother; 2008 Jun; 61(6):1328-31. PubMed ID: 18353805
[TBL] [Abstract][Full Text] [Related]
14. Vitreous and aqueous penetration of orally administered moxifloxacin in humans.
Vedantham V; Lalitha P; Velpandian T; Ghose S; Mahalakshmi R; Ramasamy K
Eye (Lond); 2006 Nov; 20(11):1273-8. PubMed ID: 16200061
[TBL] [Abstract][Full Text] [Related]
15. Bile and gallbladder tissue concentrations of moxifloxacin in patients with acute cholecystitis.
Stein GE; Smith CL; Peloquin CA; Mosher B; Dybas L; Kepros JP
Ann Pharmacother; 2010; 44(7-8):1346-7. PubMed ID: 20551298
[No Abstract] [Full Text] [Related]
16. Penetration of moxifloxacin into liver tissue.
Justinger C; Schilling MK; Kees MG; Kauffels A; Hirschmann K; Kopp B; Kees F; Kollmar O
Int J Antimicrob Agents; 2012 Jun; 39(6):505-9. PubMed ID: 22526014
[TBL] [Abstract][Full Text] [Related]
17. Determination of aqueous and vitreous concentration of moxifloxacin 0.5% after delivery via a dissolvable corneal collagen shield device.
Hariprasad SM; Shah GK; Chi J; Prince RA
J Cataract Refract Surg; 2005 Nov; 31(11):2142-6. PubMed ID: 16412929
[TBL] [Abstract][Full Text] [Related]
18. The effect of cataract surgery on ocular levels of topical moxifloxacin.
Mather R; Stewart JM; Prabriputaloong T; Wong J; McLeod SD
Am J Ophthalmol; 2004 Oct; 138(4):554-9. PubMed ID: 15488780
[TBL] [Abstract][Full Text] [Related]
19. Serum and prostatic tissue concentrations of moxifloxacin in patients undergoing transurethral resection of the prostate.
Wagenlehner FM; Lunz JC; Kees F; Wieland W; Naber KG
J Chemother; 2006 Oct; 18(5):485-9. PubMed ID: 17127224
[TBL] [Abstract][Full Text] [Related]
20. Human intraocular penetration pharmacokinetics of moxifloxacin 0.5% via topical and collagen shield routes of administration.
Hariprasad SM; Mieler WE; Shah GK; Blinder KJ; Apte RS; Holekamp NM; Thomas MA; Chi J; Prince RA
Trans Am Ophthalmol Soc; 2004; 102():149-55; discussion 155-7. PubMed ID: 15747753
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
